ArticleScientific reports2025
SIAH2-AS1 stimulates breast cancer cell proliferation and migration via the Wnt/β-catenin signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.Cancer letters · 2025Article
Corrections and comments
- Retraction · 2026-02-18Concerns/Issues about Data · Concerns/Issues about Image · Euphemisms for Plagiarism · Plagiarism of Image · Unreliable Data · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
4 authors.
Funding
Abstract
Breast cancer (BC) has become a severe threat to women, which has imposed excessive pressure on society. LncRNAs play a crucial role in the occurrence and development of BC. This study aimed to evaluate the lncRNA SIAH2 antisense RNA 1 (SIAH2-AS1) role in the development and progression of BC and explore the mechanism of SIAH2-AS1 related Wnt signaling pathway in BC. Malignant and paracancer normal breast tissue samples were obtained from patients who underwent surgery at the Second Affiliated Hospital of Zunyi Medical University. Subsequently, quantitative RT-PCR (qRT-PCR) was performed with these acquired tissue samples to evaluate the concentrations of SIAH2-AS1. Furthermore, CCK-8 assays, colony formation, wound healing, and transwell were performed to investigate the cell proliferation, migration, and invasion respectively. Western blotting was eventually performed for the investigation of proteins and EMT-related markers in the Wnt/β-catenin signaling pathway. The expression of SIAH2-AS1 was up-regulated in cancer tissues and cells. Cell proliferation, colony formation, invasiveness, and migration are significantly reduced by silencing SIAH2-AS1. Moreover, E-cadherin expression in BC cells was increased, whereas N-cadherin and vimentin expression was decreased, when SIAH2-AS1 was eliminated from the cells. Additionally, the Wnt/β-catenin signaling pathways cyclin D1 and C-myc proteins were also significantly downregulated in BC cells when SIAH2-AS1 was knocked out. Our study confirms that SIAH2-AS1 activates the Wnt/β-catenin pathway and has an oncogenic activity that promotes the prognosis of BC, suggesting that SIAH2-AS1 may be a potential drug target for BC. The development of small - molecule inhibitors capable of specifically targeting SIAH2 - AS1 to target and modify the SIAH2 - AS1 gene in cancer cells may offer a novel strategy for clinical treatment. Keywords: breast cancer; cell proliferation; cell migration; Long noncoding RNA; Wnt signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.